Neonc Technologies (NASDAQ:NTHI) CEO Thomas Chen Purchases 12,757 Shares

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Thomas Chen acquired 12,757 shares of the stock in a transaction dated Tuesday, August 18th. The stock was acquired at an average price of $5.49 per share, for a total transaction of $70,035.93. Following the completion of the acquisition, the chief executive officer directly owned 13,705 shares of the company’s stock, valued at $75,240.45. The trade was a 1,345.68% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Neonc Technologies Stock Performance

NASDAQ NTHI opened at $4.56 on Friday. Neonc Technologies Holdings, Inc. has a 52-week low of $3.01 and a 52-week high of $12.99. The firm has a 50-day moving average of $4.14 and a 200-day moving average of $5.95.

Neonc Technologies (NASDAQ:NTHI) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.46).

Hedge Funds Weigh In On Neonc Technologies

A number of institutional investors have recently modified their holdings of the stock. Bank of America Corp DE bought a new stake in shares of Neonc Technologies in the second quarter valued at about $1,017,000. BlackRock Inc. bought a new position in shares of Neonc Technologies during the 2nd quarter worth approximately $815,000. Global Retirement Partners LLC acquired a new stake in Neonc Technologies in the second quarter valued at approximately $126,000. Westmount Partners LLC increased its position in shares of Neonc Technologies by 355.2% during the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after purchasing an additional 153,858 shares in the last quarter. Finally, 683 Capital Management LLC purchased a new position in Neonc Technologies during the 4th quarter worth $442,000.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on NTHI. BTIG Research reaffirmed a “buy” rating and set a $15.00 target price on shares of Neonc Technologies in a report on Tuesday, May 26th. Wall Street Zen cut Neonc Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings downgraded Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, June 24th. Maxim Group assumed coverage on shares of Neonc Technologies in a research report on Monday, May 18th. They set a “buy” rating and a $20.00 price objective for the company. Finally, Alliance Global Partners assumed coverage on shares of Neonc Technologies in a report on Tuesday, May 19th. They issued a “buy” rating and a $13.00 target price on the stock. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Neonc Technologies has a consensus rating of “Hold” and a consensus price target of $16.00.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.